Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwMyeloma 2023

17–19 March 2023 | Madrid, Spain

iwMyeloma 2023

17–19 March 2023 | Madrid, Spain

VJHemOnc is pleased to be the official media partner for the 16th International Workshop on Myeloma (iwMyeloma), which was held in Madrid, Spain on 17-19 March 2023.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in multiple myeloma with the aim to optimize clinical care.

Click here to view the roundtable discussion for each of the sessions.

Session 1: Genomics 2023

Gareth Morgan
Biology of HR
Gareth Morgan NYU Langone Health, New York City, NY, United States
Leif  Bergsagel
The genomics and definition of SMM
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Francesco Maura
Time of origin and evolutionary trajectories to MM
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Jill  Corre
Molecular definitions of high-risk MM and their utility for trial entry
Jill Corre The Cancer University Institute of Toulouse Oncopole, Toulouse, France
Niels Weinhold
Clonal substructure and drivers of MM relapse
Niels Weinhold Heidelberg University, Heidelberg, Germany

Session 2: Overcoming treatment resistance

Irene Ghobrial
Resistance mechanisms mediated via the microenvironment
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States

Session 3: Novel targets part 1

Marta  Chesi
Using the Vk*MYC mouse model to understand early stages of myeloma
Marta Chesi Mayo Clinic, Phoenix, AZ, United States
José Ángel Martínez-Climent
Pre-clinical MM models for predicting clinical immunotherapy outcomes
José Ángel Martínez-Climent University of Navarra, Navarra, Spain
Felipe Prósper
Utility of epigenetic analysis of MM plasma cells
Felipe Prósper University of Navarra, Navarra, Spain
Maria-Victoria Mateos
Novel risk scores and endpoints for trials in SMM trials
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain

Session 4: Future of myeloma therapy

Claudia Stege
The clinical utility of frailty in clinical trial designs
Claudia Stege Amsterdam UMC, Amsterdam, Netherlands
Brian  Walker
Translational studies for MM trials in the USA
Brian Walker University of Arkansas for Medical Sciences, Little Rock, AR, United States

Session 5: Novel targets part 2

Elena  Zamagni
Utilising imaging modalities as endpoints in clinical trials
Elena Zamagni University of Bologna, Bologna, Italy
Enrique  Ocio
Other therapeutic vulnerabilities (Modakafusp, PDCs, BCL2 inhibitors)
Enrique Ocio Marqués de Valdecilla University Hospital, Santander, Spain
Carlos  Fernández De Larrea
Innovative CAR-T designs and targets
Carlos Fernández De Larrea Hospital Clínic de Barcelona, Barcelona, Spain

Session 6: Curing myeloma and how to achieve it

Pieter  Sonneveld
European perspective
Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
Sagar Lonial
US perspective
Sagar Lonial Emory Winship Cancer Institute, Atlanta, GA, United States

Session 7: T-cell engagers

Maria-Victoria Mateos
T-Cell Engagers
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Suzanne  Trudel
Suzanne Trudel Princess Margaret Cancer Centre, Toronto, Canada
Yi  Lin
Yi Lin Mayo Clinic, Rochester, MN, United States
Adam Cohen
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
Paula  Rodríguez-Otero
Paula Rodríguez-Otero University of Navarra, Navarra, Spain
Eric Smith
GPRC5D CAR T-cells
Eric Smith Dana-Farber Cancer Institute, Boston, MA, United States